Literature DB >> 28451826

Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas?

A Verger1,2,3, D Taieb4,5, E Guedj4,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28451826     DOI： 10.1007/s00259-017-3710-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  21 in total

1.  EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues.

Authors:  T Vander Borght; S Asenbaum; P Bartenstein; C Halldin; O Kapucu; K Van Laere; A Varrone; K Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11       Impact factor: 9.236

2.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

3.  Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas.

Authors:  D Ribom; A Eriksson; M Hartman; H Engler; A Nilsson; B Långström; H Bolander; M Bergström; A Smits
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas.

Authors:  A Verger; Ph Metellus; Q Sala; C Colin; E Bialecki; D Taieb; O Chinot; D Figarella-Branger; E Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-14       Impact factor: 9.236

6.  Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine?

Authors:  Gérard Moulin-Romsée; Eduard D'Hondt; Tjibbe de Groot; Jan Goffin; Raf Sciot; Luc Mortelmans; Johan Menten; Guy Bormans; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

7.  The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma.

Authors:  Veronica Villani; Carmine M Carapella; Agostino Chiaravalloti; Irene Terrenato; Francesca Piludu; Antonello Vidiri; Orazio Schillaci; Roberto Floris; Simona Marzi; Alessandra Fabi; Andrea Pace
Journal:  Anticancer Res       Date:  2015-09       Impact factor: 2.480

8.  Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo?

Authors:  K Ishiwata; K Kubota; M Murakami; R Kubota; T Sasaki; S Ishii; M Senda
Journal:  J Nucl Med       Date:  1993-11       Impact factor: 10.057

9.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Authors:  Zachary J Reitman; Genglin Jin; Edward D Karoly; Ivan Spasojevic; Jian Yang; Kenneth W Kinzler; Yiping He; Darell D Bigner; Bert Vogelstein; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 12.779

10.  D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH.

Authors:  K Oizel; C Gratas; A Nadaradjane; L Oliver; F M Vallette; C Pecqueur
Journal:  Cell Death Dis       Date:  2015-03-26       Impact factor: 9.685
View more
  11 in total

1.  A kinetic solution for the paradoxical difference between F-Dopa and methionine.

Authors:  Masashi Kameyama; Yumi Umeda-Kameyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-12       Impact factor: 9.236

2.  "The simplest explanation is usually the correct one" - Can Occam's razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?

Authors:  Egesta Lopci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08       Impact factor: 9.236

3.  A high 18F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas.

Authors:  Sibel Isal; Guillaume Gauchotte; Fabien Rech; Marie Blonski; Sophie Planel; Mohammad B Chawki; Gilles Karcher; Pierre-Yves Marie; Luc Taillandier; Antoine Verger
Journal:  Br J Radiol       Date:  2018-01-12       Impact factor: 3.039

4.  Re-evaluation of the diagnostic performance of 11C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas.

Authors:  Dongwoo Kim; Joong-Hyun Chun; Se Hoon Kim; Ju Hyung Moon; Seok-Gu Kang; Jong Hee Chang; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-17       Impact factor: 9.236

5.  Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status.

Authors:  Antoine Verger; Gabriele Stoffels; Elena K Bauer; Philipp Lohmann; Tobias Blau; Gereon R Fink; Bernd Neumaier; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-17       Impact factor: 9.236

6.  Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting.

Authors:  Johannes Haubold; Aydin Demircioglu; Marcel Gratz; Martin Glas; Karsten Wrede; Ulrich Sure; Gerald Antoch; Kathy Keyvani; Mathias Nittka; Stephan Kannengiesser; Vikas Gulani; Mark Griswold; Ken Herrmann; Michael Forsting; Felix Nensa; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-06       Impact factor: 9.236

7.  Integration of dynamic parameters in the analysis of 18F-FDopa PET imaging improves the prediction of molecular features of gliomas.

Authors:  Merwan Ginet; Timothée Zaragori; Pierre-Yves Marie; Véronique Roch; Guillaume Gauchotte; Fabien Rech; Marie Blonski; Zohra Lamiral; Luc Taillandier; Laëtitia Imbert; Antoine Verger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-16       Impact factor: 9.236

8.  Voxel-based 18F-FET PET segmentation and automatic clustering of tumor voxels: A significant association with IDH1 mutation status and survival in patients with gliomas.

Authors:  Paul Blanc-Durand; Axel Van Der Gucht; Antoine Verger; Karl-Josef Langen; Vincent Dunet; Jocelyne Bloch; Jean-Philippe Brouland; Marie Nicod-Lalonde; Niklaus Schaefer; John O Prior
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

9.  The Relationship Between IDH1 Mutation Status and Metabolic Imaging in Nonenhancing Supratentorial Diffuse Gliomas: A 11C-MET PET Study.

Authors:  Nijiati Kudulaiti; Huiwei Zhang; Tianming Qiu; Junfeng Lu; Abudumijiti Aibaidula; Zhengwei Zhang; Yihui Guan; Dongxiao Zhuang
Journal:  Mol Imaging       Date:  2019 Jan-Dec       Impact factor: 4.488

10.  Correlation of multimodal 18F-DOPA PET and conventional MRI with treatment response and survival in children with diffuse intrinsic pontine gliomas.

Authors:  Giovanni Morana; Domenico Tortora; Gianluca Bottoni; Matteo Puntoni; Gianluca Piatelli; Federica Garibotto; Salvina Barra; Flavio Giannelli; Angelina Cistaro; Mariasavina Severino; Antonio Verrico; Claudia Milanaccio; Maura Massimino; Maria Luisa Garrè; Andrea Rossi; Arnoldo Piccardo
Journal:  Theranostics       Date:  2020-10-25       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.